Topotecan

證據等級: L5

預測適應症: 10 個

Topotecan: From Established Oncology Chemotherapy to Female Breast Carcinoma

One-Sentence Summary

Topotecan is a topoisomerase I inhibitor (camptothecin derivative) already used as a chemotherapy agent in oncology — per trial data in this evidence pack (e.g., NCT01931098), it is described as a drug "used to treat lung cancer." The TxGNN model predicts it may also be effective for Female Breast Carcinoma, with 5 clinical trials and 20 publications currently identified as supporting evidence, though most are small, historical, or preclinical studies rather than confirmatory trials in this specific indication.

Quick Overview

Item	Content
Original Indication	Not documented in German license data (no BfArM authorization on file); per trial descriptions in this evidence pack, topotecan is an established chemotherapy for lung cancer and other solid tumors
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.92%
Evidence Level	L3
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data from DrugBank is not available for this candidate (flagged as a High-severity data gap, DG002). However, the repurposing rationale embedded in this evidence pack identifies topotecan as a Topoisomerase I inhibitor: it induces DNA double-strand breaks by trapping the Topo I–DNA cleavage complex, a mechanism confirmed repeatedly in the literature evidence (e.g., PMID 15836850 describes it as "a Camptothecin derivative [that] shows a large spectrum in anti-tumor activity… by inhibition of topoisomerase I activity resulting in double-strand DNA breaks").

Breast cancer cells — particularly triple-negative subtypes (MCF-7, MDA-MB-231) — have been shown in this evidence base to be Topo I-dependent and sensitive to this mechanism (PMID 40300683 identifies TFDP1 as a topotecan-responsive target in TNBC). Several older Phase II trials and pilot studies (PMID 10362325, PMID 11455218, PMID 9413954) already tested topotecan directly in advanced/metastatic breast cancer, including CNS-metastatic disease, suggesting the drug has real, if limited, clinical precedent in this population rather than being a purely computational prediction.

That said, breast cancer is not the drug's mainstream indication, current supporting trials for this specific TxGNN-predicted link are largely older, small, terminated, or of uncertain relevance (several trials in the pack are graded "C" relevance — e.g., ovarian cancer trials where topotecan's role is unclear), and no completed Phase 3 RCT specifically establishes efficacy in breast cancer. The mechanistic plausibility is reasonable, but clinical confirmation is thin.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00006032	Phase 2	Terminated	N/A	TIME regimen (topotecan + ifosfamide/mesna + etoposide) followed by autologous stem cell rescue in metastatic breast cancer; trial terminated
NCT04279509	N/A	Unknown	35	Organoid-based high-throughput drug screening platform for refractory solid tumors; not a direct efficacy trial (relevance grade C)
NCT04739800	Phase 2	Active, not recruiting	120	Durvalumab/olaparib/cediranib triplet therapy in platinum-resistant ovarian cancer; topotecan's role in this trial is not explicit (relevance grade C)
NCT02282020	Phase 3	Completed	266	Olaparib vs. physician's choice single-agent chemotherapy in gBRCA-mutated relapsed ovarian cancer; topotecan may be a comparator arm, not confirmed (relevance grade C)
NCT02419495	Phase 1	Terminated	221	Selinexor combined with standard chemo/immunotherapy regimens in advanced malignancies; topotecan-specific relevance unclear (relevance grade C)

Note: Only one trial (NCT00006032) directly and unambiguously involves topotecan in breast cancer; it was terminated. The remaining four are graded low relevance and warrant re-verification before being counted as supporting evidence.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10362325	1999	Phase II clinical trial	American Journal of Clinical Oncology	CALGB Phase II trial of topotecan in advanced/pretreated breast cancer patients (n=47 eligible)
11455218	2001	Cohort/Pilot	Onkologie	Pilot study of topotecan as primary chemotherapy for breast cancer patients with brain metastases
9413954	1997	Cohort/Pilot (Phase II)	British Journal of Cancer	Infusional topotecan in advanced breast cancer and NSCLC; no evidence of increased efficacy vs. bolus dosing
40300683	2025	Mechanistic/Preclinical	International Journal of Biological Macromolecules	TFDP1 identified as a therapeutic target for topotecan in triple-negative breast cancer
26623560	2015	Preclinical	Oncotarget	Metronomic topotecan + pazopanib shows potent efficacy in preclinical TNBC models
27444351	2016	Preclinical	Phytomedicine	MHP-1 (Cordyceps-derived) restores topotecan sensitivity via EMT/TGF-β regulation in breast cancer cells
15836850	2005	In vitro	Journal of Surgical Research	Quercetin combined with topotecan increases cytotoxicity in MCF-7 and MDA-MB-231 cells
31408695	2019	In vitro	Pharmacological Research	Daidzein enhances topotecan efficacy and reverses BCRP-mediated drug resistance in breast cancer
9445630	1997	Review	Gynäkologisch-Geburtshilfliche Rundschau	Review of new cytotoxic drugs, including topotecan, in breast carcinoma therapy
7910993	1994	Review	World Journal of Surgery	General review of systemic management options for metastatic breast cancer

Germany Market Information

Topotecan currently has no BfArM authorization records in this evidence pack — the drug is marked as not marketed in Germany (0 licenses on file).

Cytotoxicity

Topotecan is a conventional cytotoxic chemotherapy agent (camptothecin derivative, Topoisomerase I inhibitor), so this section applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Topoisomerase I inhibitor, camptothecin class)
Myelosuppression Risk	High — literature in this pack (PMID 8617580) reports myelosuppression as the major toxicity, with severe nadir counts (leukocyte, neutrophil, hemoglobin, platelet all markedly reduced)
Emetogenicity Classification	Not specified in evidence pack — please refer to the package insert warnings and precautions
Monitoring Items	Complete blood count with differential (given documented severe myelosuppression), plus standard organ function monitoring per institutional oncology protocol
Handling Protection	Requires cytotoxic drug handling precautions per standard chemotherapy handling regulations

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data for topotecan are not available in this evidence pack (flagged as Blocking data gap DG001 — TFDA/German label warnings and contraindications).

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L3 — supporting data consist mainly of small pilot/Phase II studies, preclinical/in vitro work, and reviews, with no completed pivotal trial confirming efficacy of topotecan specifically in breast cancer, and several cited trials carry low relevance grades. The drug is also not currently marketed in Germany, and a Blocking-severity safety data gap (no label warnings/contraindications) prevents any S1 safety pre-assessment.

To proceed, the following is needed:

TFDA/German label safety data (warnings, contraindications) — Blocking gap DG001
Confirmed mechanism-of-action documentation from DrugBank — High-severity gap DG002
Verification of the low-relevance ("grade C") trials to confirm whether topotecan is actually used in those regimens
Completion of "pending" literature classifications (study type/tier) to properly assess evidence strength
Clarification of topotecan's actual original/approved indication(s), since regulatory license data is currently absent
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.